More than 20 million Americans are currently affected by cataracts, and a new survey from AARP Media Sales and Alcon, the global leader in eye care, found that there are many questions and misperceptions among baby boomers about the condition, their options and how to treat it.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63529-alcon-and-a-a-r-p-mark-world-sight-day-first-live-cataract-education-event
Duchesnay USA launched a new online video series today about pregnancy health and morning sickness, which many don’t know is a medical condition called Nausea and Vomiting of Pregnancy (NVP). The series, entitled Navigating Morning Sickness, premiered with three videos about pregnancy nutrition, medication safety and the potential impact of NVP on a pregnant woman’s life. Additional new videos will be released throughout November and December.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64373-duchesnay-usa-online-video-series-pregnancy-morning-sickness
This Oceanfast 123’ motoryacht carries 4 staterooms with an on-deck master. Having undergone a major refit in 2012 including a complete paint job she shows in excellent condition and ready to go cruising. Powered by twin MTU 8V396 TE94 with the W5's completed in 2012. Perseverance II offers the interior volume and exterior space comparable to much larger yachts. Niad stabilizers, KVH V-Sat television, on-deck master, sky-lounge, tender garage and spacious sun-deck, Perseverance II stands alone in her class. Under the present ownership, she has spent a considerable amount of time cruising the East Coast, Caribbean and Great Lakes.
www.26northyachts.com
This Horizon 105 motoryacht features a 5 stateroom layout with on-deck master and huge fly-bridge for entertaining. Recently serviced twin MTU 16V2000 only have 900 hours making this motoryacht the best Horizon 105 on the market. Evan Marshall designed interior shows in excellent condition with marble floors, spacious main salon with a fully stocked bar and dining table for 10.
This Horizon 105 offers large aft deck, two garages for jet skis, walk-around decks, large fly-bridge, on-deck master, stabilizers, bow and stern thrusters, low hour MTU's and an immaculate interior that you will be proud to show.
www.26northyachts.com
The 2005 Horizon 78\\\\\\\' Bella Mare shows in excellent condition, conveniently located minutes from the Fort Lauderdale Airport. Bella Mare carries a three stateroom layout plus crew quarters powered by twin MAN engines at 1550 hp apiece. Featuring an enclosed Sky-Lounge, Country Kitchen, and full beam Main Salon, she offers the interior volume of a much larger yacht. Other features include hydraulic bow and stern thruster, TRAC stabilizers, chilled A/C, water maker and more. The 11\\\\\\\' Boston Whaler can easily be boarded from the large swim platform that\\\\\\\'s a perfect setup whether your an avid diver or fisherman.
Eisai Inc. today announced the launch of My Healthy™, an interactive and motivational campaign that shifts the focus of the obesity conversation away from just pounds lost to health gained. Almost 70 percent of Americans are affected by obesity or overweight. This movement emphasizes that those affected by obesity or overweight with a related health condition can benefit from small positive changes, including modest weight loss.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7131331-eisai-inc-my-healthy-promise-liberate-your-closet/
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the initiation of production of The PBA Film Project (working title), the first-ever documentary to provide an intimate look at real people living with a little-known neurologic condition called PseudoBulbar Affect (PBA). The award-winning filmmaker team of The PBA Film Project includes co-directors Doug Blush and Lisa Klein (Of Two Minds) and producer Julian Cautherley (The Crash Reel).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7266955-avanir-pharmaceuticals-pseudobulbar-affect-pba-documentary/
EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7269351-enteromedics-fda-approval-vbloc-maestro-system-weight-loss-device/
The latest lash breakthrough is here. From Rimmel, you can get the Moroccan Argan oil your hair loves in a Rimmel mascara with new Wonder’lash Mascara with Argan Oil. Condition lashes and break through clumps for full, smooth volume. The unique brush’s super-soft bristles hug and coat each lash, perfectly separating them from root to tip. Even small corner lashes are dramatically transformed for an effortlessly eye-catching look. Lashes are left smoother, sleeker, and more defined than ever.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7428651-rimmel-london-wonder-lash/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Top of the mountain, five percent battery remaining, no outlet in sight. Decision time: go back or keep going? Adventurers can now go further in almost any condition with FRĒ Power from LifeProof, doubling the battery life of iPhone 6.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7525051-lifeproof-announces-fre-power/
